We recently compiled a list of the Louis Navellier’s Top 15 Long-Term Stock Picks. In this article, we are going to take a ...

Shares of AbbVie Inc. ABBV rallied 1.37% to $173.70 Thursday, on what proved to be an all-around rough trading session for ...

AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company, stands at a critical juncture as it navigates the loss of ...

AbbVie Inc. closed $31.77 below its 52-week high ($207.32), which the company reached on October 31st.

Stock analysts at Zacks Research decreased their FY2024 EPS estimates for AbbVie in a research report issued to clients and investors on Wednesday, January 15th. Zacks Research analyst S. Ganoria now ...

AbbVie Inc (ABBV) stock saw a modest uptick, ending the day at $173.7 which represents a slight increase of $2.35 or 1.37% from the prior close of $171.35. The stock opened at $171.45 and touched a ...

Leerink Partners analyst David Risinger has reiterated their bullish stance on ABBV stock, giving a Buy rating yesterday.Stay Ahead of the ...

In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other best dividend king stocks to invest in now. Investing in dividend stocks has been a focal point ...

Abbvie Inc. and Simcere Zaiming Pharmaceutical Co. Ltd. are part of the volley of large deals accompanying the opening of the ...

Shares of AbbVie have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+11.7% vs. -2.2%). The ...

Shares of AbbVie Inc. (NYSE:ABBV – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the ...